Highbridge Capital Management LLC Takes $549,000 Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Highbridge Capital Management LLC acquired a new position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 300,000 shares of the biopharmaceutical company’s stock, valued at approximately $549,000. Highbridge Capital Management LLC owned about 1.15% of Inovio Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. BNP Paribas Financial Markets raised its holdings in shares of Inovio Pharmaceuticals by 177.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 3,630 shares during the period. MetLife Investment Management LLC raised its holdings in Inovio Pharmaceuticals by 129.1% in the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 8,546 shares during the period. Atom Investors LP acquired a new position in Inovio Pharmaceuticals during the third quarter valued at approximately $103,000. FMR LLC grew its stake in Inovio Pharmaceuticals by 370.1% during the third quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 21,462 shares during the period. Finally, Barclays PLC increased its position in shares of Inovio Pharmaceuticals by 282.6% in the third quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock worth $197,000 after acquiring an additional 25,116 shares in the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

INO has been the topic of several recent research reports. Royal Bank of Canada reduced their target price on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 19th. JMP Securities restated a “market outperform” rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright reiterated a “neutral” rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. Finally, StockNews.com upgraded Inovio Pharmaceuticals to a “sell” rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.20.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $1.76 on Friday. The firm has a market cap of $45.94 million, a PE ratio of -0.44 and a beta of 0.92. Inovio Pharmaceuticals, Inc. has a 1 year low of $1.71 and a 1 year high of $14.75. The firm’s 50-day simple moving average is $2.03 and its 200-day simple moving average is $3.58.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.18. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.03 million. On average, equities analysts predict that Inovio Pharmaceuticals, Inc. will post -4.23 earnings per share for the current year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.